Profusa (PFSA) Stock Price, News & Analysis

Company Overview

Profusa, Inc. is a medical technology company focused on developing implantable and tissue-integrated biosensors for continuous monitoring of health-related data. Its technology is designed to use small, injectable sensors that interact with the body and transmit information to external devices, potentially reducing the need for repeated blood draws or other intermittent testing.

The company’s product development efforts have included the Lumee Oxygen Sensing System, an implantable sensor platform intended to measure tissue oxygen levels. Profusa has also explored applications for monitoring other biomarkers and supporting remote patient monitoring, clinical research, and personalized healthcare.

Profusa was founded in the United States and has conducted development and regulatory activities in the U.S. and Europe. The company became publicly traded under the Nasdaq symbol PFSA following a business combination, although publicly available information about its current commercial operations and leadership is limited.

Key Stats

• Today's Range: $1.67 to $1.83
• 50-Day Range: $1.69 to $27.48
• 52-Week Range: $1.58 to $3,000.00
• Volume: 200,622 shs
• Average Volume: 944,811 shs
• Market Capitalization: $1.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Profusa Stock Analysis - MarketRank™

Profusa scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Profusa has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Profusa has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Profusa is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Profusa is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.13% of the float of Profusa has been sold short.

Short Interest Ratio / Days to Cover

Profusa has a short interest ratio ("days to cover") of 0.12, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Profusa has recently decreased by 20.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Profusa does not currently pay a dividend.

Dividend Growth

Profusa does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

Profusa has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Profusa this week, compared to 3 articles on an average week.

Search Interest

9 people have searched for PFSA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Profusa insiders have sold 127.45% more of their company's stock than they have bought. Specifically, they have bought $16,594.00 in company stock and sold $37,743.00 in company stock.

Percentage Held by Insiders

15.00% of the stock of Profusa is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

9.81% of the stock of Profusa is held by institutions.

Company Calendar

• Last Earnings: 8/19/2026
• Today: 10/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:PFSA
• CIK: 1859807
• Web: profusa.com
• Phone: (212) 494-9022
• Fax: N/A
• Employees: 2
• Year Founded: 2009

Profitability

• EPS (Trailing Twelve Months): ($5,619.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,731.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.03
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: $100 thousand
• Price / Sales: 10.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2,168.90) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 610,000
• Free Float: 515,000
• Market Cap: $1.06 million
• Optionable: N/A
• Beta: 0.53